Forecast

The analysts' average price target is €7.74 (+187.73%). The median is €7.74 (+187.73%).

Buy	4
Hold	0
Sell	0

News Go to news feed

Evaxion rises after pipeline progress and confirms funding runway through H2 2027

Evaxion reported a net loss of $3.7m for Q2 2026 and said its cash runway and spending plan secure operations into the second half of 2027. Investors reacted positively to progress with EVX-01 (personalized melanoma vaccine; three-year data expected in October), AML candidate EVX-04 (regulatory filing planned by end-2026) and the early glioblastoma program EVX-05. The stock rose about 5.4% in premarket trading to $3.32 but remains well below its 52-week high; management emphasizes disciplined spending and potential partnerships to further extend the runway. » More on de.investing.com
Evaxion reports Q2 loss and announces three-year data on cancer vaccine EVX-01

Evaxion posted a net loss of USD 3.7 million in the second quarter, with R&D expenses of USD 2.3 million and administrative costs of USD 1.5 million. As of June 30, cash and cash equivalents stood at USD 14.0 million, sufficient to fund operations into the second half of 2027, while equity fell to USD 9.5 million. The company will present three‑year data on its personalized cancer vaccine candidate EVX-01 at the ESMO congress in October and plans to file an application for clinical testing of EVX-04 before year-end. Evaxion is also expanding its pipeline with EVX-05 against glioblastoma in collaboration with Duke University and presented data on EVX-V1 and EVX-04 at professional conferences. » More on de.investing.com
Evaxion presents three-year data on EVX-01 in melanoma study at ESMO

Evaxion will present three-year data from its Phase 2 study of the personalized cancer vaccine candidate EVX-01 at the ESMO congress. The two-year data showed an objective response rate of 75% (12 of 16 patients) and four complete remissions; after two years 92% of responders remained relapse-free, and tumor reduction was documented in 15 of 16 patients. In the third year patients received EVX-01 as monotherapy following prior combined treatment with pembrolizumab, and the vaccine induced immune responses in all patients. Evaxion has a market capitalization of around $26 million, the stock is down about 35% year-to-date, analysts see price targets of $9–16 and InvestingPro rates the stock as undervalued. » More on de.investing.com

Financials

In the last quarter, EVAXION BIOTECH SP.ADS/10 Aktie had revenue of €0 and net profit of -€3.26M

(EUR)	June 2026	YoY
Revenue	0	100.00%
Gross profit	0	100.00%
Net profit	-3.26M	20.40%
EBITDA	-3.37M	17.11%

Fundamentals

Metric	Value
Market capitalization	€16.95M
Number of shares	6.32M
52-week high/low	€10.45 - €2.33
Dividends	No
Beta	0.27
P/E ratio	-0.51
PEG ratio	0.00
P/B ratio	0.14
P/S ratio	2.63

Company profile

Evaxion Biotech A/S, ein Biotech-Unternehmen in der klinischen Phase, entwickelt durch künstliche Intelligenz unterstützte Immuntherapien für Krebs, bakterielle Erkrankungen und Virusinfektionen. Das Unternehmen entwickelt EVX-01, eine Krebsimmuntherapie, die sich in einer klinischen Phase-IIb-Studie für das metastasierende Melanom befindet; EVX-02, eine DNA-basierte Krebsimmuntherapie, die sich in einer Phase-IIa-Studie für das adjuvante Melanom befindet; und EVX-03, eine DNA-basierte Immuntherapie für die Behandlung verschiedener Krebsarten. Zu den Programmen des Unternehmens gehören auch EVX-B1, EVX-B2 und EVX-V1, bei denen es sich um Impfstoffe handelt, die sich in der präklinischen Phase zur Behandlung von bakteriellen und viralen Krankheiten befinden. Das Unternehmen wurde 2008 gegründet und hat seinen Hauptsitz in Hørsholm, Dänemark.

Name	EVAXION BIOTECH SP.ADS/10 Aktie
CEO	Helen Katrina Tayton-Martin
Headquarters	Horsholm, nd Denmark
Website	evaxion-biotech.com
Industry	Food Products
IPO	02/05/2021
Employees	46